{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RLD&page=2",
    "query": {
      "intervention": "RLD",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RLD&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T07:23:19.500Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03896633",
      "title": "Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Open Angle or Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "brinzolamide 1% ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Azopt 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 637,
      "start_date": "2018-02-28",
      "completion_date": "2018-11-17",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896633"
    },
    {
      "nct_id": "NCT03433378",
      "title": "To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tretinoin cream, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "RETIN-A® (tretinoin) cream, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of the test product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 700,
      "start_date": "2017-08-04",
      "completion_date": "2018-01-26",
      "has_results": false,
      "last_update_posted_date": "2018-05-18",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03433378"
    },
    {
      "nct_id": "NCT03271983",
      "title": "Pharmacokinetics of Metronidazole Dermal Products",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Bioequivalence"
      ],
      "interventions": [
        {
          "name": "Metronidazole gel 1",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole gel 2",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-04-09",
      "completion_date": "2019-11-03",
      "has_results": true,
      "last_update_posted_date": "2022-05-17",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03271983"
    },
    {
      "nct_id": "NCT06689436",
      "title": "Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Random Allocation",
        "Intermittent Fasting",
        "Enteral Feeding"
      ],
      "interventions": [
        {
          "name": "5 mg Apixaban Oral Dissolving Film (fasting)",
          "type": "DRUG"
        },
        {
          "name": "5 mg Apixaban Oral Dissolving Film (fed)",
          "type": "DRUG"
        },
        {
          "name": "5 mg Apixaban Oral Tablet (US RS/RLD)",
          "type": "DRUG"
        },
        {
          "name": "5 mg Apixaban Oral Tablet (EU product)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TAHO Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-11-16",
      "completion_date": "2025-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-11",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06689436"
    },
    {
      "nct_id": "NCT05986591",
      "title": "Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Test Product - Tiotropium Bromide Inhalation Powder 18 mcg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Spiriva Handihaler (Tiotropium Bromide) 18 mcg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Xiromed LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 335,
      "start_date": "2022-08-17",
      "completion_date": "2023-08-14",
      "has_results": false,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05986591"
    },
    {
      "nct_id": "NCT03427554",
      "title": "To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tretinoin cream 0.1%",
          "type": "DRUG"
        },
        {
          "name": "RETIN-A® Cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of the test product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 455,
      "start_date": "2017-08-21",
      "completion_date": "2018-01-26",
      "has_results": false,
      "last_update_posted_date": "2018-05-18",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03427554"
    },
    {
      "nct_id": "NCT04321070",
      "title": "Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Clindamycin Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin Phosphate RLD",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 550,
      "start_date": "2019-09-09",
      "completion_date": "2020-03-06",
      "has_results": false,
      "last_update_posted_date": "2025-04-10",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04321070"
    },
    {
      "nct_id": "NCT03200912",
      "title": "An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ACTINIC KERATOSIS"
      ],
      "interventions": [
        {
          "name": "Ingenol Mebutate (Picato®)",
          "type": "DRUG"
        },
        {
          "name": "Generic Ingenol Mebutate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 507,
      "start_date": "2016-08-19",
      "completion_date": "2017-03-22",
      "has_results": true,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 23,
      "location_summary": "Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more",
      "locations": [
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03200912"
    },
    {
      "nct_id": "NCT05322707",
      "title": "BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg",
          "type": "DRUG"
        },
        {
          "name": "Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cipla Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1485,
      "start_date": "2022-04-15",
      "completion_date": "2023-08-29",
      "has_results": false,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Medford, Oregon",
      "locations": [
        {
          "city": "Medford",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05322707"
    },
    {
      "nct_id": "NCT03909750",
      "title": "Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD",
        "Respiratory Insufficiency"
      ],
      "interventions": [
        {
          "name": "Lipoaspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "AD-cSVF",
          "type": "PROCEDURE"
        },
        {
          "name": "Normal Saline IV",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Healeon Medical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-04-10",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-09-08T07:23:19.500Z",
      "location_count": 1,
      "location_summary": "Stevensville, Montana",
      "locations": [
        {
          "city": "Stevensville",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03909750"
    }
  ]
}